CO5560558A2 - Uso de una composicion de celecoxib para rapido alivio del dolor - Google Patents
Uso de una composicion de celecoxib para rapido alivio del dolorInfo
- Publication number
- CO5560558A2 CO5560558A2 CO02106745A CO02106745A CO5560558A2 CO 5560558 A2 CO5560558 A2 CO 5560558A2 CO 02106745 A CO02106745 A CO 02106745A CO 02106745 A CO02106745 A CO 02106745A CO 5560558 A2 CO5560558 A2 CO 5560558A2
- Authority
- CO
- Colombia
- Prior art keywords
- celecoxib
- pain relief
- subject
- composition
- minutes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
1.- Un método terapéutico que comprende administrar oralmente a un sujeto mamífero en necesidad de analgesia una cantidad efectiva de alivio del dolor de una composición que comprende celecoxib formulado en forma tal de proporcionar, cuando se prueba en humanos de acuerdo con la práctica farmacocinética estándar, un perfil de concentración de plasma de sangre de celecoxib donde una concentración de por lo menos alrededor de 250 ng/ml se logra no más tarde de alrededor de 30 minutos después de la administración oral.2.- Un método terapéutico para rápido alivio del dolor en un sujeto mamífero en necesidad de él, el método que comprende administrar oralmente al sujeto, una composición que comprende celecoxib en una formulación que proporciona una efectiva concentración de plasma de alivio del dolor de por lo menos alrededor de 250 ng/ml no más tarde de alrededor de 30 minutos después de la administración oral.3.- Un método terapéutico para analgesia en un sujeto mamífero en necesidad de él, el método que comprende administrar oralmente al sujeto, una composición que comprende celecoxib en una formulación que proporciona detectable alivio del dolor no más tarde de alrededor de 30 minutos después la administración oral.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20772900P | 2000-05-26 | 2000-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5560558A2 true CO5560558A2 (es) | 2005-09-30 |
Family
ID=22771755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO02106745A CO5560558A2 (es) | 2000-05-26 | 2002-11-25 | Uso de una composicion de celecoxib para rapido alivio del dolor |
Country Status (21)
Country | Link |
---|---|
US (2) | US6579895B2 (es) |
EP (1) | EP1283710A1 (es) |
JP (1) | JP2003534376A (es) |
KR (1) | KR20030019397A (es) |
CN (1) | CN1444478A (es) |
AR (1) | AR035642A1 (es) |
AU (2) | AU2001265013B2 (es) |
BR (1) | BR0111186A (es) |
CA (1) | CA2408793A1 (es) |
CO (1) | CO5560558A2 (es) |
CZ (1) | CZ20023794A3 (es) |
EA (1) | EA200201124A1 (es) |
IL (1) | IL152870A0 (es) |
MX (1) | MXPA02011624A (es) |
MY (1) | MY120279A (es) |
NO (1) | NO20025631L (es) |
NZ (1) | NZ522624A (es) |
PE (1) | PE20011326A1 (es) |
PL (1) | PL359170A1 (es) |
WO (1) | WO2001091750A1 (es) |
ZA (1) | ZA200209313B (es) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040013613A1 (en) * | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US8293277B2 (en) | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US20040115134A1 (en) * | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
US6800297B2 (en) * | 2000-06-15 | 2004-10-05 | Acusphere, Inc. | Porous COX-2 inhibitor matrices and methods of manufacture thereof |
US6589557B2 (en) | 2000-06-15 | 2003-07-08 | Acusphere, Inc. | Porous celecoxib matrices and methods of manufacture thereof |
CA2415697A1 (en) * | 2000-07-13 | 2002-01-24 | James C. Forbes | Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain |
US7071220B2 (en) * | 2000-09-18 | 2006-07-04 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
US7198795B2 (en) | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
US20030105144A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
SE0102886D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
SE0102888D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
SE0102887D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
ATE383156T1 (de) * | 2001-11-13 | 2008-01-15 | Pharmacia Corp | Oral verabreichbare zusammensetzung enthaltend parecoxib |
WO2003049720A1 (en) * | 2001-12-07 | 2003-06-19 | Merck & Co., Inc. | Combination therapy comprising a cyclooygenase-2 inhibitor |
PT1471887E (pt) | 2002-02-04 | 2010-07-16 | Elan Pharma Int Ltd | Composiães de nanopartculas com lisozima como um estabilizador superficial |
US20090088443A1 (en) * | 2002-02-15 | 2009-04-02 | Julius Remenar | Novel crystalline forms of conazoles and methods of making and using the same |
US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US20030224006A1 (en) | 2002-03-01 | 2003-12-04 | Zaworotko Michael J. | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
US20050025791A1 (en) | 2002-06-21 | 2005-02-03 | Julius Remenar | Pharmaceutical compositions with improved dissolution |
CN100444839C (zh) * | 2002-03-18 | 2008-12-24 | 先灵公司 | 式(i)化合物在制备治疗化学激活物中介的疾病的药物中的应用 |
US20080220075A1 (en) * | 2002-03-20 | 2008-09-11 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
AU2003230691A1 (en) * | 2002-03-20 | 2003-10-08 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
IL164163A0 (en) * | 2002-04-09 | 2005-12-18 | Pharmacia Corp | Process for preparing a finely self-emulsifiable pharmaceutical composition |
US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
GB0209257D0 (en) * | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
WO2003103632A1 (en) * | 2002-06-10 | 2003-12-18 | Elan Pharma International, Ltd. | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
US20060052432A1 (en) * | 2002-09-20 | 2006-03-09 | Julius Remenar | Pharmaceutical compositions with improved dissolution |
WO2004037245A1 (en) * | 2002-10-03 | 2004-05-06 | Pharmacia & Upjohn Company | Combination of a growth hormone receptor antagonist such as pegvisomant and a cox-2 inhibitor such as celecoxib for the treatment of headache in patients with acromegaly |
SI3241550T1 (sl) | 2002-11-22 | 2020-11-30 | Grunenthal Gmbh | Uporaba (1R, 2R) -3- (3-dimetilimanino-1-etil-2-metil-propil)-fenola za zdravljenje vnetnih bolečin |
US20060148877A1 (en) * | 2002-11-26 | 2006-07-06 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations of celcoxib |
EP1935407A1 (en) * | 2002-12-03 | 2008-06-25 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
EP2339328A3 (en) | 2002-12-30 | 2011-07-13 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of celecoxib |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
US20100297252A1 (en) | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
US8512727B2 (en) | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
ITMI20032523A1 (it) | 2003-12-19 | 2005-06-20 | Acraf | Forma di dosaggio per uso orale comprendente un farmaco |
US7638331B2 (en) | 2004-01-02 | 2009-12-29 | The Administration of the Tulane Rducation Fund | Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery |
ES2341461T5 (es) * | 2004-02-11 | 2014-10-29 | Warner-Lambert Company Llc | Procedimientos de tratamiento de la artrosis con anticuerpos ANTI-IL-6 |
WO2005099691A1 (en) * | 2004-03-31 | 2005-10-27 | Pharmacia & Upjohn Company Llc | Composition for treating elevated intraocular pressure |
WO2006062875A1 (en) * | 2004-12-08 | 2006-06-15 | Merck & Co., Inc. | Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor |
EP1858542A4 (en) * | 2005-02-24 | 2009-08-19 | Joslin Diabetes Center Inc | COMPOSITIONS AND METHODS FOR TREATING VASCULAR PERMEABILITY |
US20100119512A1 (en) * | 2007-01-25 | 2010-05-13 | Joslin Diabetes Center | Methods of diagnosing, treating, and preventing increased vascular permeability |
CA2683940A1 (en) * | 2007-04-20 | 2008-10-30 | University Of South Australia | Nanoparticle-coated capsule formulation for dermal drug delivery |
EP2222282A1 (en) * | 2007-11-15 | 2010-09-01 | Pfizer Products Inc. | Dosage forms comprising celecoxib providing both rapid and sustained pain relief |
US8778400B2 (en) * | 2008-04-21 | 2014-07-15 | University Of South Australia | Nanoparticle-stabilized capsule formulation for treatment of inflammation |
JP2011519926A (ja) * | 2008-05-05 | 2011-07-14 | ウィンスロップ−ユニバーシティー ホスピタル | Cox阻害薬の心血管系リスク因子の改善方法 |
FR2937553B1 (fr) * | 2008-10-29 | 2011-01-07 | Biocodex | Combinaison synergique de composes analgesiques |
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
US20110033545A1 (en) * | 2009-08-06 | 2011-02-10 | Absize, Inc. | Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith |
MX337893B (es) * | 2009-11-10 | 2016-03-28 | Celgene Corp | Nanosuspension de un farmaco debilmente soluble preparada por un proceso de microfluidizacion. |
ES2749096T3 (es) | 2012-10-25 | 2020-03-19 | Massachusetts Gen Hospital | Terapias de combinación para el tratamiento de la enfermedad de Alzheimery transtornos relacionados |
US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
WO2015061397A1 (en) | 2013-10-22 | 2015-04-30 | The General Hostpital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
JP6605047B2 (ja) * | 2015-05-28 | 2019-11-13 | ドクター・レディーズ・ラボラトリーズ・リミテッド | 疼痛治療のためのセレコキシブの経口用組成物 |
MX2017015202A (es) * | 2015-05-29 | 2018-07-06 | Codadose Incorporated | Formulaciones liquidas de celecoxib para administracion oral. |
HUP1500618A2 (en) | 2015-12-16 | 2017-06-28 | Druggability Tech Ip Holdco Ltd | Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them |
WO2018045217A1 (en) | 2016-08-31 | 2018-03-08 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
KR20210070232A (ko) | 2017-07-20 | 2021-06-14 | 아즈테라피즈 인코포레이티드 | 크로몰린 나트륨 및 이부프로펜의 분말화된 제형 |
EP3817739A4 (en) | 2018-07-02 | 2022-04-13 | The General Hospital Corporation | SODIUM CROMOGLYCATE AND ?-LACTOSE POWDER FORMULATIONS |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
FR2634376B1 (fr) | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
JP4439590B2 (ja) | 1992-06-10 | 2010-03-24 | エラン ファーマ インターナショナル,リミティド | 表面改質nsaidナノ粒子 |
AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US5340564A (en) | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
NZ536355A (en) | 1993-11-30 | 2006-08-31 | Searle & Co | Method of treating inflammation using substituted pyrazolyl benzenesulfonamides |
US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5569448A (en) | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5571536A (en) | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5560931A (en) | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5503723A (en) | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
CZ292320B6 (cs) | 1995-05-25 | 2003-09-17 | G. D. Searle & Co. | Způsob přípravy pyrazolů |
DE69637441T2 (de) | 1995-10-17 | 2009-03-05 | Jagotec Ag | Verabreichung unlöslicher arzneistoffe |
WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
CA2202345A1 (en) * | 1997-03-07 | 1998-09-07 | Cameron Black | 2-(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cox-2 |
IL140276A0 (en) | 1998-06-19 | 2002-02-10 | Rtp Pharma Inc | Processes to generate submicron particles of water-insoluble compounds |
JP2002525311A (ja) | 1998-10-01 | 2002-08-13 | エラン ファーマ インターナショナル,リミティド | 徐放性ナノ粒子組成物 |
WO2000025779A1 (en) * | 1998-11-02 | 2000-05-11 | Merck & Co., Inc. | Method of treating migraines and pharmaceutical compositions |
CA2350531A1 (en) * | 1998-11-13 | 2000-05-25 | Smriti Iyengar | Method for treating pain |
AU767737B2 (en) | 1998-11-20 | 2003-11-20 | Skyepharma Canada Inc. | Method of preparing stable suspensions of insoluble microparticles |
SA99191255B1 (ar) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
BR0010984A (pt) * | 1999-05-27 | 2002-04-30 | Acusphere Inc | Matrizes porosas de medicamento e processos para fabricação das mesmas |
NZ519467A (en) * | 1999-12-22 | 2004-02-27 | Pharmacia Corp | Dual-release compositions of a cyclooxygenase-2- inhibitor |
-
2001
- 2001-05-24 MY MYPI20012477A patent/MY120279A/en unknown
- 2001-05-24 AR ARP010102524A patent/AR035642A1/es unknown
- 2001-05-25 EA EA200201124A patent/EA200201124A1/ru unknown
- 2001-05-25 NZ NZ522624A patent/NZ522624A/en unknown
- 2001-05-25 US US09/866,165 patent/US6579895B2/en not_active Expired - Fee Related
- 2001-05-25 PE PE2001000481A patent/PE20011326A1/es not_active Application Discontinuation
- 2001-05-25 PL PL01359170A patent/PL359170A1/xx not_active Application Discontinuation
- 2001-05-25 EP EP01939502A patent/EP1283710A1/en not_active Withdrawn
- 2001-05-25 JP JP2001587765A patent/JP2003534376A/ja active Pending
- 2001-05-25 WO PCT/US2001/017083 patent/WO2001091750A1/en not_active Application Discontinuation
- 2001-05-25 BR BR0111186-8A patent/BR0111186A/pt not_active Application Discontinuation
- 2001-05-25 KR KR1020027015982A patent/KR20030019397A/ko not_active Application Discontinuation
- 2001-05-25 AU AU2001265013A patent/AU2001265013B2/en not_active Ceased
- 2001-05-25 IL IL15287001A patent/IL152870A0/xx unknown
- 2001-05-25 CN CN01813357A patent/CN1444478A/zh active Pending
- 2001-05-25 AU AU6501301A patent/AU6501301A/xx active Pending
- 2001-05-25 CZ CZ20023794A patent/CZ20023794A3/cs unknown
- 2001-05-25 CA CA002408793A patent/CA2408793A1/en not_active Abandoned
- 2001-05-25 MX MXPA02011624A patent/MXPA02011624A/es unknown
-
2002
- 2002-11-15 ZA ZA200209313A patent/ZA200209313B/en unknown
- 2002-11-22 NO NO20025631A patent/NO20025631L/no not_active Application Discontinuation
- 2002-11-25 CO CO02106745A patent/CO5560558A2/es not_active Application Discontinuation
- 2002-12-27 US US10/330,946 patent/US20030134887A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2001265013B2 (en) | 2006-07-06 |
JP2003534376A (ja) | 2003-11-18 |
CN1444478A (zh) | 2003-09-24 |
AU6501301A (en) | 2001-12-11 |
ZA200209313B (en) | 2003-11-17 |
NZ522624A (en) | 2004-08-27 |
US20030134887A1 (en) | 2003-07-17 |
PL359170A1 (en) | 2004-08-23 |
EA200201124A1 (ru) | 2003-06-26 |
BR0111186A (pt) | 2003-06-10 |
CZ20023794A3 (cs) | 2003-12-17 |
EP1283710A1 (en) | 2003-02-19 |
US6579895B2 (en) | 2003-06-17 |
NO20025631D0 (no) | 2002-11-22 |
AR035642A1 (es) | 2004-06-23 |
IL152870A0 (en) | 2003-06-24 |
CA2408793A1 (en) | 2001-12-06 |
WO2001091750A1 (en) | 2001-12-06 |
MY120279A (en) | 2005-09-30 |
NO20025631L (no) | 2003-01-22 |
KR20030019397A (ko) | 2003-03-06 |
MXPA02011624A (es) | 2004-05-17 |
PE20011326A1 (es) | 2002-02-06 |
US20020028238A1 (en) | 2002-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5560558A2 (es) | Uso de una composicion de celecoxib para rapido alivio del dolor | |
CO5680109A1 (es) | Compuestos para el tratamiento de la disfuncion sexual femenina | |
CL2009001682A1 (es) | Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00). | |
AR033444A1 (es) | Forma solida de dosificacion util para la administracion oral de un compuesto activo de nicotina, a traves de la mucosa y uso de un compuesto activo de nicotina para prepararla | |
ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
MA27265A1 (fr) | Formulations d'agoniste opioide a antagoniste liberable et sequestre | |
ES8505519A1 (es) | Un procedimiento para la preparacion de 14-fluoromorfinanos utiles como analgesicos, narcoticos y-o agentes anorexicos. | |
CO5261517A1 (es) | Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosis | |
BR0109150A (pt) | Método para administração de um anestésico local a um indivìduo em necessidade de um efeito anestésico local, emplastro, composição, e, recipiente | |
ES2110377T1 (es) | Formulacion galenica de fenofibrato y aplicacion de la misma. | |
AR012671A1 (es) | Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos | |
UY27533A1 (es) | Composiciones farmacéuticas que contienen oxibutinina | |
KR970706815A (ko) | 온단세트론을 포함하는 경구 조성물(Oral Compositions Containing Ondansetron) | |
UA82979C2 (ru) | Фармацевтическая композиция, пригодная для перорального введения, которая содержит no-высвобождающие нспвл, лекарственная форма, фармацевтическая комбинация и способы лечения | |
AR008293A1 (es) | Composicion que comprende una cantidad antihistaminica para el tratamiento de las respuestas alergicas de las vias respiratorias superiores | |
EE04606B1 (et) | H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks | |
AR012417A1 (es) | COMPOSICIoN FARMACÉUTICA DE ADMINISTRACIoN ORAL Y PROCEDIMIENTO PARA SU PRODUCCION. | |
ATE15596T1 (de) | Pharmazeutische mittel. | |
AR034813A1 (es) | Composiciones farmaceuticas y uso de las mismas | |
CO5570661A2 (es) | Combinaciones que comprenden inhibidores de cox-2 y aspirina | |
EP1064966A3 (en) | Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine | |
DK1280558T3 (da) | Halvfast indgivelsesvehikel og farmaceutiske sammensætninger | |
BRPI0412430A (pt) | polipeptìdeo agonista do receptor de zot e zonulina | |
PE12098A1 (es) | Composiciones y metodos para tratar transtornos respiratorios | |
SE8204288L (sv) | Analgetisk komposition innehallande n-acetyl-p-aminofenol i kombination med ett antacidum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |